loader image

Our Company

About Us

Minovia Therapeutics is the first company to use cell therapy approach to treat mitochondrial diseases. Our proprietary Mitochondrial Augmentation Therapy (MAT) platform is designed to treat the underlying cause of mitochondrial diseases by using autologous stem cells augmented with healthy mitochondria. Our goal is to bring life changing therapies improving mitochondrial patients’ lives.

Our initial clinical focus are rare mitochondrial diseases for which there are no approved treatments. Following a compassionate use program, MAT was designated as an investigational drug and is undergoing a clinical trial in Pearson Syndrome, an Ultra-Rare, fatal pediatric disease.

We are committed to exploring the full potential of MAT to address mitochondrial diseases, ranging from orphan indications to more common age-related diseases.